Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have been assigned an average rating of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $41.00.

OLMA has been the topic of a number of research analyst reports. JPMorgan Chase & Co. upped their price target on shares of Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Wednesday, October 8th. Oppenheimer lifted their price target on shares of Olema Pharmaceuticals from $45.00 to $48.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. Piper Sandler began coverage on Olema Pharmaceuticals in a report on Wednesday, January 7th. They issued an “overweight” rating and a $40.00 price target for the company. Finally, Guggenheim assumed coverage on Olema Pharmaceuticals in a report on Wednesday, October 8th. They set a “buy” rating and a $20.00 price objective on the stock.

Insider Transactions at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 2,881 shares of the stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $28.53, for a total transaction of $82,194.93. Following the transaction, the director directly owned 741,259 shares in the company, valued at $21,148,119.27. This represents a 0.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ian T. Clark sold 264,800 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $29.73, for a total transaction of $7,872,504.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 588,190 shares of company stock worth $17,038,578 over the last quarter. 16.36% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Olema Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Kingdon Capital Management L.L.C. purchased a new position in Olema Pharmaceuticals during the third quarter valued at approximately $8,361,000. Ameriprise Financial Inc. boosted its position in Olema Pharmaceuticals by 193.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,172,863 shares of the company’s stock valued at $4,996,000 after acquiring an additional 773,064 shares in the last quarter. Candriam S.C.A. increased its holdings in shares of Olema Pharmaceuticals by 46.9% in the 3rd quarter. Candriam S.C.A. now owns 1,249,727 shares of the company’s stock valued at $12,235,000 after acquiring an additional 399,273 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Olema Pharmaceuticals by 93.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 741,329 shares of the company’s stock worth $2,787,000 after acquiring an additional 358,412 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in shares of Olema Pharmaceuticals by 4,450.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 299,619 shares of the company’s stock worth $2,933,000 after purchasing an additional 293,034 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

Olema Pharmaceuticals Price Performance

Shares of OLMA stock opened at $28.08 on Monday. Olema Pharmaceuticals has a 52-week low of $2.86 and a 52-week high of $36.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03. The firm has a market capitalization of $1.93 billion, a P/E ratio of -15.02 and a beta of 1.92. The stock has a 50 day moving average price of $23.06 and a 200 day moving average price of $12.55.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05). As a group, sell-side analysts predict that Olema Pharmaceuticals will post -2.33 earnings per share for the current year.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.